In this second video on refractory thyroid cancer, Marcia Brose, MD, reviews recent findings from clinical practice and evolving clinical trials in the context of tyrosine kinase inhibitor therapy for refractory thyroid cancer. Among the subjects Dr. Brose considers are the addition of the mTOR inhibitor everolimus to therapy for patients whose disease is progressing on sorafenib, vemurafenib in patients with BRAF V600E-positive progressive papillary thyroid cancer and the Phase 1 trial of cabozantinib.
Related Links
Published
September 23, 2015
Created by
BROADCASTMED